CORRECTING and REPLACING Butterfly Network Reports Second Quarter 2025 Financial Results
Delivered Highest Quarterly Revenue and Gross Margins in Company History
-
Quarterly Revenue of
$23.4 million in Q2, representing 9% YoY growth, and Gross Margins of 64% -
Reduced quarterly Cash Used to
$7.1 million , the lowest of any quarter - Revised full year Revenue guidance and improved Adjusted EBITDA guidance
The updated release reads:
Delivered Highest Quarterly Revenue and Gross Margins in Company History
-
Quarterly Revenue of
$23.4 million in Q2, representing 9% YoY growth, and Gross Margins of 64% -
Reduced quarterly Cash Used to
$7.1 million , the lowest of any quarter - Revised full year Revenue guidance and improved Adjusted EBITDA guidance
DeVivo continued, “As we look ahead, we remain focused on scaling our core business, while unlocking new revenue streams by leveraging our existing technology. Handheld ultrasound is becoming a foundational part of care delivery, and with our Compass AI software coming soon, as well as our P5 chip and fourth-generation technology on the horizon, we're poised to continue leading that shift. We will continue innovating across hardware and software to expand adoption and maximize the value of the platform we’ve built.”
Recent Operational and Strategic Highlights:
-
Butterfly Garden Growth: Two new partners were added to the portfolio in Q2, while three existing partners received FDA clearance for their AI-powered clinical applications: iCardio, HeartFocus by DESKi, and Deep Echo. HeartFocus expects to launch to Butterfly users in Q3, with the other applications launching shortly thereafter.
-
New Educational Resources: Butterfly released a new Aorta Exam Protocol on its ScanLab™ educational software, helping users learn to scan for conditions like abdominal aortic aneurysms. Additionally, through Butterfly Garden, the
University of Rochester Medical Center launched MSK VUE, an AI-powered musculoskeletal ultrasound training app for Butterfly devices, designed to help clinicians identify key peripheral structures.
-
Clinical Research: New research from
Tufts University published inEuropean Heart Journal - Imaging Methods and Practice demonstrated that a machine learning model specifically trained to work on Butterfly iQ+ devices can accurately detect aortic stenosis. Additionally, the full findings from theRutgers Robert Wood Johnson Medical School andRobert Wood Johnson University Hospital study previewed earlier this year have now been accepted into a prominent medical journal for publication in Q3.
-
Announcing Compass AI: Next-generation, cloud-based enterprise software platform is expected to launch in Q3, and aims to further optimize documentation processes through new, advanced AI tools and other enhancements like automated voice control to capture caregivers' notes and auto-populate fields in seconds.
-
Butterfly HomeCare Progress: Concluded pilot program, which demonstrated meaningful reductions in readmissions for congestive heart failure patients being managed at risk. The Company and partner are now working toward completion of their first commercial agreement, aiming to deploy the Butterfly HomeCare solution in the partner's first state before the end of the year.
Three Months Ended
Revenue: Total revenue was
Gross profit: Gross profit was
Operating expenses: Operating expenses were
Net loss: Net loss was
Adjusted EBITDA: Adjusted EBITDA loss was
Adjusted EPS: Adjusted EPS was
Cash and cash equivalents: Cash and cash equivalents were
Guidance
Revised Revenue guidance and improved Adjusted EBITDA guidance for the Fiscal Year 2025:
-
Revenue of
$91 million to$95 million or approximately 13% growth -
Adjusted EBITDA loss of
$32 million -$37 million
Chief Financial and Operations Officer Transition
Effective today,
Effective upon Ms. Getz’s resignation,
Butterfly has begun the process of engaging a search firm to assist in identifying Ms. Getz’s replacement.
“On behalf of our employees and Board of Directors, I want to thank Heather for her more than three years of dedicated service. We value the discipline she instilled across the organization, and under her leadership Butterfly strengthened its balance sheet and delivered on its financial commitments to shareholders. We wish her every success in her future endeavors,” said Butterfly CEO
“It has been a privilege to serve on Butterfly’s leadership team, and I am proud of our accomplishments during my tenure,” said
Reconciliation of GAAP to Adjusted
Reconciliations of gross margin to adjusted gross margin and of net loss to adjusted EBITDA and adjusted EPS for the three and six months ended
Conference Call
A conference call and webcast to discuss second quarter 2025 financial performance and operational progress is scheduled for
US domestic callers: +1 833-470-1428
International (Toll): +1 404-975-4839
Global Dial-In Numbers:https://www.netroadshow.com/conferencing/global-numbers?confId=82507
Access Code: 685760
After the live webcast, the call will be archived on Butterfly’s Investor Relations page. In addition, a telephone replay of the call will be available until
Access Code: 128350
About
Butterfly combines advanced hardware, intelligent software, AI, services, and education to drive adoption of affordable, accessible imaging. Clinical publications demonstrate that its handheld ultrasound probes paired with Compass™ enterprise workflow software, can help hospital systems improve care workflows, reduce costs, and enhance provider economics. With a cloud-based solution that enables care anywhere through next-generation mobility, Butterfly aims to democratize healthcare by addressing critical global healthcare challenges. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of
Non-GAAP Financial Measures
In addition to providing financial measures based on generally accepted accounting principles in
The non-GAAP financial measures included in this press release are key performance measures that our management uses to assess our operating performance. These non-GAAP measures facilitate internal comparisons of our operating performance on a more consistent basis. We use these performance measures for business planning purposes and forecasting. We believe that these non-GAAP measures enhance an investor’s understanding of our financial performance as they are useful in assessing our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business.
The non-GAAP financial measures included in this press release may not be comparable to similarly titled measures of other companies because they may not calculate these measures in the same manner. These non-GAAP financial measures are not prepared in accordance with GAAP and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. When evaluating the Company’s performance, you should consider adjusted gross profit, adjusted gross margin, adjusted EBITDA, and adjusted EPS alongside other financial performance measures prepared in accordance with GAAP, including gross profit, gross margin, net loss, and EPS.
The non-GAAP financial measures do not replace the presentation of our GAAP financial results and should only be used as a supplement to, not as a substitute for, our financial results presented in accordance with GAAP. In this press release, we have provided reconciliations of adjusted gross profit to gross profit, adjusted gross margin to gross margin, and adjusted EBITDA and adjusted EPS to net loss, the most directly comparable GAAP financial measures. Reconciliations of our non-GAAP financial measures to corresponding GAAP measures are not available on a forward-looking basis because we are unable to predict with reasonable certainty the non-cash component of employee compensation expense, changes in our working capital needs, variances in our supply chain, the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations, and other such items without unreasonable effort. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.
Forward Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Our actual results may differ from our expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believe,” “predict,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, our expectations with respect to financial results, future performance, commercialization and plans to deploy our products and services, including expectations regarding the launches of our Compass AI software, our P5 chip and fourth-generation technology, and the HeartFocus launch to Butterfly users, development of products and services, and the size and potential growth of current or future markets for our products and services. Forward-looking statements are based on our current beliefs and assumptions and on information currently available to us. These forward-looking statements involve significant known and unknown risks and uncertainties and other factors that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside our control and are difficult to predict. Factors that may cause such differences include, but are not limited to: our ability to grow and manage growth effectively; the success, cost, and timing of our product and service development activities; the potential attributes and benefits of our products and services; the degree to which our products and services are accepted by healthcare practitioners and patients for their approved uses; our ability to obtain and maintain regulatory approval for our products, and any related restrictions and limitations on the use of any authorized product; our ability to identify, in-license, or acquire additional technology; our ability to maintain our existing license, manufacturing, supply, and distribution agreements; our ability to compete with other companies currently marketing or engaged in the development of ultrasound imaging devices, many of which have greater financial and marketing resources than us; changes in applicable laws or regulations; the size and growth potential of the markets for our products and services, and our ability to serve those markets, either alone or in partnership with others; the pricing of our products and services, and reimbursement for medical procedures conducted using our products and services; our estimates regarding expenses, revenue, capital requirements, and needs for additional financing; our financial performance; our ability to attract and retain customers; our ability to manage our growth effectively; our ability to protect or enforce our intellectual property rights; our ability to maintain the listing of our Class A common stock on the
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share amounts) (Unaudited) |
||||||||||||||||
Three months ended |
Six months ended |
|||||||||||||||
2025 |
2024 |
2025 |
2024 |
|||||||||||||
Revenue: | ||||||||||||||||
Product | $ |
16,621 |
|
$ |
14,648 |
|
$ |
30,785 |
|
$ |
25,939 |
|
||||
Software and other services |
6,762 |
|
6,839 |
|
13,823 |
|
13,204 |
|
||||||||
Total revenue |
23,383 |
|
21,487 |
|
44,608 |
|
39,143 |
|
||||||||
Cost of revenue: | ||||||||||||||||
Product |
6,670 |
|
6,579 |
|
12,494 |
|
11,674 |
|
||||||||
Software and other services |
1,822 |
|
2,322 |
|
3,842 |
|
4,606 |
|
||||||||
Total cost of revenue |
8,492 |
|
8,901 |
|
16,336 |
|
16,280 |
|
||||||||
Gross profit |
14,891 |
|
12,586 |
|
28,272 |
|
22,863 |
|
||||||||
Operating expenses: | ||||||||||||||||
Research and development |
8,315 |
|
9,411 |
|
18,239 |
|
20,131 |
|
||||||||
Sales and marketing |
11,559 |
|
9,728 |
|
23,179 |
|
20,106 |
|
||||||||
General and administrative |
9,130 |
|
10,073 |
|
18,729 |
|
20,514 |
|
||||||||
Other |
1,987 |
|
606 |
|
2,691 |
|
1,964 |
|
||||||||
Total operating expenses |
30,991 |
|
29,818 |
|
62,838 |
|
62,715 |
|
||||||||
Loss from operations |
(16,100 |
) |
(17,232 |
) |
(34,566 |
) |
(39,852 |
) |
||||||||
Interest income |
1,503 |
|
1,291 |
|
3,155 |
|
2,802 |
|
||||||||
Interest expense |
(368 |
) |
(309 |
) |
(715 |
) |
(609 |
) |
||||||||
Change in fair value of warrant liabilities |
620 |
|
620 |
|
1,446 |
|
413 |
|
||||||||
Other income (expense), net |
531 |
|
(59 |
) |
2,906 |
|
(201 |
) |
||||||||
Loss before provision for income taxes |
(13,814 |
) |
(15,689 |
) |
(27,774 |
) |
(37,447 |
) |
||||||||
Provision for income taxes |
20 |
|
17 |
|
27 |
|
20 |
|
||||||||
Net loss and comprehensive loss | $ |
(13,834 |
) |
$ |
(15,706 |
) |
$ |
(27,801 |
) |
$ |
(37,467 |
) |
||||
Net loss per common share attributable to Class A and B common stockholders, basic and diluted | $ |
(0.06 |
) |
$ |
(0.07 |
) |
$ |
(0.12 |
) |
$ |
(0.18 |
) |
||||
Weighted-average shares used to compute net loss per share attributable to Class A and B common stockholders, basic and diluted |
248,393,811 |
|
211,663,554 |
|
241,695,884 |
|
210,268,501 |
|
CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) (Unaudited) |
||||||||
2025 |
2024 |
|||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ |
148,136 |
|
$ |
88,775 |
|
||
Accounts receivable, net of allowance for doubtful accounts of |
24,527 |
|
20,793 |
|
||||
Inventories |
68,907 |
|
70,789 |
|
||||
Current portion of vendor advances |
4,555 |
|
5,547 |
|
||||
Prepaid expenses and other current assets |
7,622 |
|
6,709 |
|
||||
Total current assets |
253,747 |
|
192,613 |
|
||||
Property and equipment, net |
17,329 |
|
19,518 |
|
||||
Intangible assets, net |
8,216 |
|
8,916 |
|
||||
Non-current portion of vendor advances |
14,790 |
|
15,042 |
|
||||
Operating lease assets |
13,461 |
|
14,233 |
|
||||
Other non-current assets |
5,735 |
|
5,760 |
|
||||
Total assets | $ |
313,278 |
|
$ |
256,082 |
|
||
Liabilities and stockholders’ equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ |
3,320 |
|
$ |
4,250 |
|
||
Deferred revenue, current |
15,642 |
|
16,139 |
|
||||
Accrued purchase commitments, current |
131 |
|
131 |
|
||||
Warrant liabilities, current |
1,239 |
|
— |
|
||||
Accrued expenses and other current liabilities |
24,334 |
|
27,695 |
|
||||
Total current liabilities |
44,666 |
|
48,215 |
|
||||
Deferred revenue, non-current |
7,231 |
|
7,315 |
|
||||
Warrant liabilities, non-current |
— |
|
2,685 |
|
||||
Operating lease liabilities |
19,097 |
|
20,398 |
|
||||
Other non-current liabilities |
9,478 |
|
8,637 |
|
||||
Total liabilities |
80,472 |
|
87,250 |
|
||||
Commitments and contingencies | ||||||||
Stockholders’ equity: | ||||||||
Class A common stock |
22 |
|
19 |
|
||||
Class B common stock |
3 |
|
3 |
|
||||
Additional paid-in capital |
1,062,712 |
|
970,940 |
|
||||
Accumulated deficit |
(829,931 |
) |
(802,130 |
) |
||||
Total stockholders’ equity |
232,806 |
|
168,832 |
|
||||
Total liabilities and stockholders’ equity | $ |
313,278 |
|
$ |
256,082 |
|
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) |
||||||||
Six months ended |
||||||||
2025 |
2024 |
|||||||
Cash flows from operating activities: | ||||||||
Net loss | $ |
(27,801 |
) |
$ |
(37,467 |
) |
||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation, amortization, and impairments |
4,442 |
|
5,217 |
|
||||
Non-cash interest expense |
713 |
|
607 |
|
||||
Write-down of inventories |
66 |
|
(81 |
) |
||||
Stock-based compensation expense |
12,148 |
|
11,383 |
|
||||
Change in fair value of warrant liabilities |
(1,446 |
) |
(413 |
) |
||||
Other |
172 |
|
462 |
|
||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable |
(3,909 |
) |
(3,165 |
) |
||||
Inventories |
1,816 |
|
(1,072 |
) |
||||
Prepaid expenses and other assets |
(874 |
) |
165 |
|
||||
Vendor advances |
1,244 |
|
(1,396 |
) |
||||
Accounts payable |
(927 |
) |
(587 |
) |
||||
Deferred revenue |
(581 |
) |
(908 |
) |
||||
Change in operating lease assets and liabilities |
(411 |
) |
(348 |
) |
||||
Accrued expenses and other liabilities |
(3,496 |
) |
(3,064 |
) |
||||
Net cash used in operating activities |
(18,844 |
) |
(30,667 |
) |
||||
Cash flows from investing activities: | ||||||||
Purchases of property, equipment, and intangible assets, including capitalized software |
(1,249 |
) |
(1,872 |
) |
||||
Sales of property and equipment |
— |
|
35 |
|
||||
Net cash used in investing activities |
(1,249 |
) |
(1,837 |
) |
||||
Cash flows from financing activities: | ||||||||
Proceeds from exercise of stock options and warrants |
274 |
|
— |
|
||||
Proceeds from employee stock purchase plan |
949 |
|
— |
|
||||
Net proceeds from share offering |
81,006 |
|
— |
|
||||
Payments to tax authorities for restricted stock units withheld |
(2,775 |
) |
— |
|
||||
Net cash provided by financing activities |
79,454 |
|
— |
|
||||
Net increase (decrease) in cash, cash equivalents, and restricted cash |
59,361 |
|
(32,504 |
) |
||||
Cash, cash equivalents, and restricted cash, beginning of period |
92,790 |
|
138,650 |
|
||||
Cash, cash equivalents, and restricted cash, end of period | $ |
152,151 |
|
$ |
106,146 |
|
ADJUSTED GROSS PROFIT AND ADJUSTED GROSS MARGIN (In thousands) (Unaudited) |
||||||||||||||||
Three months ended |
Six months ended |
|||||||||||||||
2025 |
2024 |
2025 |
2024 |
|||||||||||||
Revenue | $ |
23,383 |
$ |
21,487 |
$ |
44,608 |
$ |
39,143 |
||||||||
Cost of revenue |
8,492 |
8,901 |
16,336 |
16,280 |
||||||||||||
Gross profit | $ |
14,891 |
$ |
12,586 |
$ |
28,272 |
$ |
22,863 |
||||||||
Gross margin |
63.7 |
% |
58.6 |
% |
63.4 |
% |
58.4 |
% |
||||||||
Add: | ||||||||||||||||
Write-downs and write-offs of inventories |
14 |
— |
66 |
— |
||||||||||||
Adjusted gross profit | $ |
14,905 |
$ |
12,586 |
$ |
28,338 |
$ |
22,863 |
||||||||
Adjusted gross margin |
63.7 |
% |
58.6 |
% |
63.5 |
% |
58.4 |
% |
||||||||
Depreciation and amortization | $ |
1,138 |
$ |
1,646 |
$ |
2,541 |
$ |
3,231 |
||||||||
% of revenue |
4.9 |
% |
7.7 |
% |
5.7 |
% |
8.3 |
% |
ADJUSTED EBITDA AND ADJUSTED EPS (In thousands, except share and per share amounts) (Unaudited) |
|||||||||||||||||
Included on the condensed consolidated statements of operations and comprehensive loss as: |
Three months ended |
Six months ended |
|||||||||||||||
2025 |
2024 |
2025 |
2024 |
||||||||||||||
Net loss | Net loss | $ |
(13,834 |
) |
$ |
(15,706 |
) |
$ |
(27,801 |
) |
$ |
(37,467 |
) |
||||
Stock-based compensation | R& |
5,864 |
|
5,859 |
|
12,148 |
|
11,383 |
|
||||||||
Write-downs and write-offs of inventories | Cost of revenue |
14 |
|
— |
|
66 |
|
— |
|
||||||||
Change in fair value of warrant liabilities | Change in fair value of warrant liabilities |
(620 |
) |
(620 |
) |
(1,446 |
) |
(413 |
) |
||||||||
Other | Other |
1,987 |
|
606 |
|
2,691 |
|
1,964 |
|
||||||||
Other expense (income), net | Other income (expense), net |
(531 |
) |
59 |
|
(2,906 |
) |
201 |
|
||||||||
Adjusted net loss |
(7,120 |
) |
(9,802 |
) |
(17,248 |
) |
(24,332 |
) |
|||||||||
Interest income | Interest income |
(1,503 |
) |
(1,291 |
) |
(3,155 |
) |
(2,802 |
) |
||||||||
Interest expense | Interest expense |
368 |
|
309 |
|
715 |
|
609 |
|
||||||||
Provision for income taxes | Provision for income taxes |
20 |
|
17 |
|
27 |
|
20 |
|
||||||||
Depreciation and amortization | Cost of revenue, R& |
2,082 |
|
2,633 |
|
4,442 |
|
5,217 |
|
||||||||
Adjusted EBITDA | $ |
(6,153 |
) |
$ |
(8,134 |
) |
$ |
(15,219 |
) |
$ |
(21,288 |
) |
|||||
Adjusted EPS | $ |
(0.03 |
) |
$ |
(0.05 |
) |
$ |
(0.07 |
) |
$ |
(0.12 |
) |
|||||
Weighted average shares used to compute adjusted EPS |
248,393,811 |
|
211,663,554 |
|
241,695,884 |
|
210,268,501 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20250801374436/en/
Investors
Director, Communications & Public Relations, Butterfly
investors@butterflynetwork.com
Managing Director,
shalper@lifesciadvisors.com
Source: